BBLGW
Bone Biologics Corp (BBLG, BBLGW
NASDAQ · Healthcare · Medical - Devices · US
$7.70
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +10.8%
- EBIT
- +25.7%
- EPS
- +33.6%
- Free cash flow
- +22.8%
- Operating cash flow
- +22.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +89.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- +23.3%
- Net income
- +24.4%
- EPS
- +45.1%
- Free cash flow
- +34.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026